Reduction of Postherpetic Neuralgia in Herpes Zoster

Part of paid clinical trials in Houston, Texas.

Sponsor
Center for Clinical Studies, Texas
Study ID
NCT01250561
Status
Completed

Conditions

  • Herpes Zoster
  • Post-herpetic Neuralgia

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gabapentin — DRUG
    gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
  • Valacyclovir — DRUG
    valacyclovir 1000mg three-times daily x 7 days

Study Details

The addition of gabapentin therapy to standard antiviral treatment with valacyclovir in acute herpes zoster patients will decrease the incidence of post-herpetic neuralgia.

Key Dates

First listed
Dec 1, 2010
Start date
Feb 28, 2002
Status verified
Nov 2010
Primary completion
Oct 31, 2007
Completion
Oct 31, 2007

Study Design

Enrollment
133 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Proportion of patients with zoster pain at 6 months

Locations (1)

FacilityCityStateZIPSite coordinators
Center for Clinical StudiesHoustonTexas77030-

Find similar trials in Houston, TX

By research site
Center for Clinical Studies· Houston, TX

Related Studies